友霖生技醫藥股份有限公司
友霖生技醫藥股份有限公司（Orient Pharma Co., Ltd.）在台灣及國際市場開發新藥。提供心血管藥物如 Pitator 及 Tonvasca 用於調節血脂；以及中樞神經系統藥物如長效型抗癲癇藥與過動症藥物。公司成立於 2008 年，總部位於台灣台北。為友華集團子公司。
今日下跌 1.80%，股價跌破短期均線。該股 RSI(6) 為 31.9，處於中性區間，短線無明顯超買超賣訊號。股價跌破5日、20日、60日、120日均線。KD 指標中性（K=31.1）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-10 | -52 | 0 | 0 | -52 |
| 08-07 | +22 | 0 | 0 | +22 |
| 08-06 | -2 | 0 | 0 | -2 |
| 08-05 | -2 | 0 | 0 | -2 |
| 08-04 | -9 | 0 | 0 | -9 |
| 08-03 | +33 | 0 | 0 | +33 |
| 07-31 | -125 | 0 | 0 | -125 |
| 07-30 | +14 | 0 | 0 | +14 |
| 07-29 | +30 | 0 | +4 | +34 |
| 07-28 | -34 | 0 | 0 | -34 |
| 07-27 | -26 | 0 | 0 | -26 |
| 07-24 | +115 | 0 | 0 | +115 |
| 07-23 | -158 | 0 | 0 | -158 |
| 07-22 | -15 | 0 | 0 | -15 |
| 07-21 | -3 | 0 | 0 | -3 |
| 07-20 | +5 | 0 | 0 | +5 |
| 07-17 | +82 | 0 | 0 | +82 |
| 07-16 | +89 | 0 | +9 | +98 |
| 07-15 | -2 | 0 | 0 | -2 |
| 07-14 | +54 | 0 | 0 | +54 |
| 07-13 | -21 | 0 | 0 | -21 |
| 07-09 | -21 | 0 | 0 | -21 |
| 07-08 | +87 | 0 | 0 | +87 |
| 07-07 | +369 | 0 | 0 | +369 |
| 07-06 | +87 | 0 | 0 | +87 |
| 07-03 | +34 | 0 | 0 | +34 |
| 07-02 | -46 | 0 | 0 | -46 |
| 07-01 | -92 | 0 | 0 | -92 |
| 06-30 | +109 | 0 | 0 | +109 |
| 06-29 | +24 | 0 | 0 | +24 |
| 06-26 | -16 | 0 | 0 | -16 |
| 06-25 | +103 | 0 | 0 | +103 |
| 06-24 | +84 | 0 | 0 | +84 |
| 06-23 | +40 | 0 | 0 | +40 |
| 06-22 | -17 | 0 | 0 | -17 |
| 06-18 | +28 | 0 | 0 | +28 |
| 06-17 | -36 | 0 | 0 | -36 |
| 06-16 | -55 | 0 | 0 | -55 |
| 06-15 | -15 | 0 | 0 | -15 |
| 06-12 | +61 | 0 | 0 | +61 |
| 06-11 | -365 | 0 | 0 | -366 |
| 06-10 | -65 | 0 | +731 | -63 |
| 06-09 | -19 | 0 | 0 | -19 |
| 06-08 | +46 | 0 | 0 | +46 |
| 06-05 | +29 | 0 | 0 | +29 |
| 06-04 | +14 | 0 | 0 | +14 |
| 06-03 | -47 | 0 | 0 | -47 |
| 06-02 | -10 | 0 | 0 | -10 |
| 06-01 | -116 | 0 | 0 | -116 |
| 05-29 | -95 | 0 | 0 | -95 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 1.31 億 | +21.8% | - |
| 2026/03 | 1.08 億 | +37.6% | - |
| 2026/02 | 7820 萬 | -46.2% | - |
| 2026/01 | 1.45 億 | +10.4% | - |
| 2025/12 | 1.32 億 | -17.7% | - |
| 2025/11 | 1.60 億 | +6.7% | - |
| 2025/10 | 1.50 億 | +42.3% | - |
| 2025/09 | 1.05 億 | +4.5% | - |
| 2025/08 | 1.01 億 | -8.1% | - |
| 2025/07 | 1.10 億 | +0.9% | - |
| 2025/06 | 1.09 億 | - | - |